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Cardiotoxicity resulting from exposure to
environmental toxicants and pollutants has
been known for a long time (1). However, a
detailed examination of cardiac toxic effects
and investigations of the mechanisms of car-
diotoxicity had not been undertaken until
recently. In fact, cardiotoxicology was not a
defined discipline in the past. Two major
advances in biomedical research and practice
have made an urgent need for cardiotoxico-
logic studies. First, it is now an exciting time
in the history of cardiovascular medicine.
New drugs and devices are invented for the
treatment of heart disease on a weekly basis
(2). Undoubtedly some of these drugs and
procedures will have cardiotoxic effects. For
every new treatment, it will be essential to
thoroughly assess toxic effects on the heart.
Second, the application of cutting-edge mol-
ecular biology approaches has provided sig-
nificant and novel insights into cardiac
toxicity and its mechanisms (3,4).
Mechanistic studies on cardiovascular effects
of environmental toxicants and pollutants
have emerged at a very fast pace. We have
just begun to understand cellular events and
molecular mechanisms of cardiotoxicity. A
survey of our current knowledge in this excit-
ing ﬁeld will help to identify gaps that need
to be filled. There are excellent textbooks
(5–7) describing basic anatomic, biochemi-
cal, and physiologic principles of the heart
from humans to experimental animals.
Ultrastructural and histologic changes of the
heart in toxic injury have also been elaborated
in detail (8–10). This review thus only
focuses on cellular events, signaling pathways,
and molecular mechanisms of cardiotoxicity,
with a brief review, if necessary, of bridging
knowledge leading to the focused discussion. 
Myocardial Responses 
to Environmental Toxicants
The foremost changes in the early phase of
responses of myocardium to environmental
toxicants involve alterations in biochemical
reactions. These include the most often
described alterations in ionic homeostasis such
as changes in intracellular calcium concentra-
tions, which occur in almost all examined expo-
sures to environmental toxicants to date
(11,12). Aberrant energy metabolism is another
early response to environmental toxicants in the
heart, resulting in decreased production and/or
enhanced consumption of adenosine triphos-
phate (ATP) (13,14). Alterations in enzymatic
reactions are often described in cardiac toxic
responses (15), although we know very little
about these alterations. The early signaling
pathways leading to myocardial toxic responses
are the recent focus of cardiotoxicologic
research (16,17). Detailed descriptions of these
pathways and their roles in cardiotoxicity are
yet to be explored. It is likely that activation of
early genes and signaling pathways is a critical
response of myocardial cells to environmental
toxic insults (18). The cross-talk between sig-
naling pathways determines the ultimate out-
come of myocardial responses to environmental
toxicants and pollutants.
Physiologic alterations occur both as early
responses to environmental toxicants and as
subsequent events in the late development of
cardiomyopathy. The most obvious myocar-
dial dysfunction that occurs in the early
responses to toxicants is cardiac arrhythmia
(19), which often results from the changes in
intracellular calcium concentrations and other
biochemical alterations, leading to miscommu-
nication between cells and misconduction of
electricity (20). These changes, if not accompa-
nied by cardiomyopathy, do not involve
myocardial cell death and are reversible. The
late phase of cardiac dysfunction, however,
often results from cardiomyopathy. 
Changes in myocardial morphology take
place when extensive toxic insults are
imposed on the heart and/or toxic exposures
persist on a long-term basis (21–23). Cardiac
hypertrophy is often observed as a conse-
quence of long-term toxic insults. The hyper-
trophy is considered a protective and adaptive
response. However, further hypertrophy leads
to severe and irreversible cardiomyopathy,
eventually resulting in heart failure (24–26).
From cardiac hypertrophy to heart failure,
activation of compensatory mechanisms
including the sympathetic nerve system and
the renin–angiotensin system takes place
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(27,28). The compensatory response in turn
activates counterregulatory mechanisms such
as upregulation of atrial natriuretic peptide
(ANP) expression (29,30). These responses
collectively lead to extensive biochemical,
physiologic, and molecular changes, eventu-
ally myocardial remodeling (31–33), and
remarkable cell death. These changes ulti-
mately result in heart failure. Figure 1 depicts
these mechanisms. Most cardiotoxicologic
studies address fundamental and characteris-
tic changes during this stage of myocardial
responses to toxic insults. The ultimate tar-
gets and the determining units of cardiotoxic-
ity are cardiac cells. In this context, the
following sections will be devoted to discus-
sion of the cellular events, molecular mecha-
nisms, and signaling pathways that are
involved in the myocardial responses to toxic
insults. 
Cellular Events Involved 
in Cardiotoxicity
Toxic insults trigger a series of reactions in
cardiac cells leading to measurable changes in
myocardial morphology, biochemistry, and
physiology. Mild injuries can be repaired;
however, severe injuries lead to cell death in
the form of apoptosis and necrosis. If the cell
survives the insults, structural and functional
adaptations take place. 
Myocardial Apoptosis 
Myocardial apoptosis, which is involved in
cardiomyopathy, was ﬁrst recognized in 1994
(34). Recent progress in myocardial research
has provided signiﬁcant insights into the cellu-
lar mechanisms of cardiotoxicity. It has been
recognized that the loss of cardiac myocytes is
a fundamental part of the myocardial injury
that initiates or aggravates cardiomyopathy
and leads to premature death (35–37). An
important mode of myocardial cell loss is
apoptosis (38–40), which has been demon-
strated in the myocardium of heart failure
patients (41,42). In our early studies, we have
found that dietary copper restriction causes
cardiomyopathy, which is accompanied with
apoptosis in rat hearts (43). Myocardial apop-
tosis has been shown to play an important role
in cardiac toxic effects induced by adriamycin
(44), an important anticancer agent whose
clinical application is limited by its major side
effect, cardiotoxicity (45). Exposure of pri-
mary cultures of cardiomyocytes to cadmium
also induces apoptosis (46). 
Many in vivo studies have shown that
only a very small percentage of myocardial
cell populations undergo apoptosis under
pathologic conditions (47,48). For example,
we have observed that less than 0.5% of cells
appeared apoptotic in myocardial tissue
obtained from copper-deﬁcient mice (49). At
first glance, this number seems to be too
insignificant to account for myocardial
pathogenesis. However, this is a false assess-
ment. In a carefully designed time course
study (50), it has been estimated that car-
diomyocyte apoptosis may be completed in
less than 20 hr in rats. Because the heart is a
terminally differentiated organ, myocytes
undergoing apoptosis are lost and are not
replaced. Thus, the total cell loss can simply
be accounted for by the rate of apoptosis plus
necrosis. If apoptosis occurs at a constant
rate of about 0.5% myocytes a day (49), the
potential contribution of apoptosis to the
overall loss of myocytes over a long period of
time is signiﬁcant.
Myocardial Necrosis 
The term myocardial necrosis has been
widely used to describe myocardial cell death
in the past. Myocardial infarction, in particu-
lar, was considered a consequence of necrosis
(51). It is now recognized that apoptosis con-
tributes significantly to the formation of
myocardial infarction (52), although the con-
sequence of apoptosis in this pathogenesis is
yet to be defined. However, the significance
of necrosis in myocardial pathogenesis cannot
be underestimated. The contribution of
necrosis to cardiomyopathy induced by envi-
ronmental toxicants and pollutants is particu-
larly important. A critical issue is how to
distinguish between apoptosis and necrosis. 
Apoptosis and necrosis were originally
described as two distinct forms of cell
death that can be clearly distinguished (53).
However, these two modes of cell death can
occur simultaneously in tissues and cultured
cells (54). The intensity and duration of insults
may decide the outcome (55). Thus, triggering
events can be common for both types of cell
death. A downstream controller, however, may
direct cells toward a programmed execution of
apoptosis. If the apoptotic program is aborted
before this control point and the initiating
stimulus is severe, cell death may occur by
necrosis (56). Alternatively, in acute injury,
apoptotic cells can progress along a continuum
to eventual necrosis.
It is important to note that apoptosis is
an energy-dependent process and that the
switch in the decision between apoptosis and
necrosis depends on ATP concentrations
(57). In particular, conditions causing
ischemia to myocardial cells result in signiﬁ-
cant reduction and eventual depletion of
adenine nucleotides. ATP loss of more than
70% of the total pool present in myocardial
cells has been shown to cause a switch from
apoptosis to necrosis (56,58). This extent of
depletion of the ATP pool is often observed
in myocardial infarction. 
Identification of apoptotic and necrotic
cell death processes requires more rigorous
methods than have been generally used.
Artifacts inherent in techniques that detect
double-stranded DNA breaks as well as
overlaps between apoptotic and necrotic death
programs account for these problems (59,60).
Current assays are limited in their capacities to
distinguish between apoptosis and necrosis in
myocytes. In addition, distinguishing between
myocyte and nonmyocyte apoptosis in the
myocardium is another problem to overcome.
In our recent studies examining adriamycin-
induced myocardial apoptosis (61), we used an
in situ terminal deoxynucleotidyl–transferase-
mediated dUTP nick end labeling (TUNEL)
assay in combination with a dual immunohis-
tochemical detection of α-sarcomeric actin, a
specific protein present in cardiomyocytes.
This procedure thus identified whether the
TUNEL-positive cells were myocytes. Another
procedure we used was immuno-gold TUNEL
and electron microscopic examination of the
apoptotic cells (61). It is well known that the
gold standard for identification of apoptotic
cells is morphologic examination by electron
microscopy. This immuno-gold TUNEL and
electron microscopic procedure thus provides
information about cell type and morphologic
characteristics of apoptotic cells.
Myocardial Adaptation 
Myocardial adaptation is the general process
by which the ventricular myocardium
changes in structure and function. This
process is often referred to as “remodeling.”
During maturation, myocardial remodeling is
a normal feature that is a useful adaptation to
Figure 1. Myocardial responses to environmental toxic
insults leading to heart failure, including important cel-
lular events, signaling pathways, and neurohumoral
regulations.
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increased demands. However, in response to
pathologic stimuli such as exposure to envi-
ronmental toxicants, myocardial remodeling
is adaptive in the short term but maladaptive
in the long term and often eventuates in fur-
ther myocardial dysfunction. The central fea-
ture of myocardial remodeling is an increase
in myocardial mass associated with a change
in the shape of the ventricle (62).
Molecular Mechanisms
Involved in Cardiotoxicity
The most severe and early response of
myocardium to overwhelming environmental
toxic insults is cell death by apoptosis and
necrosis. Myocardial cells, like other cells, are
equipped with cell death programs and con-
tain preexisting death machinery. In response
to environmental toxic insults, these pro-
grams are activated. At the same time, cyto-
protective mechanisms are also turned on,
such as activation of antiapoptotic factors
including the Bcl-2 family. Therefore,
whether a cell will die depends on the balance
between the activities of cell death programs
and the cytoprotective mechanisms. The sig-
naling pathways leading to activation of cell
death program are discussed below.
Although cell death is the ultimate end
point that is often measured in assessing
myocardial responses to environmental toxic
insults (63,64), cellular and molecular events
leading to myocardial remodeling are critical
parameters of cardiotoxicity. The foremost
observation of myocardial morphologic
change in response to stimuli is heart hyper-
trophy. Although the hypertrophic response
initially is a compensatory mechanism that
augments cardiac output, sustained hypertro-
phy can lead to dilated cardiomyopathy, heart
failure, and sudden death (65,66). A series of
prototypical molecular responses of cardio-
myocytes to environmental stimuli includes
an increase in cell size and protein synthesis
(67), enhanced sarcomeric organization (68),
upregulation of fetal cardiac genes (69,70),
and induction of immediate–early genes
(71,72). These responses collectively lead to
cardiac hypertrophy. 
Myocardial Gene Regulation 
Myocardial gene regulation in response to
toxic insults is not well understood. However,
extensive studies on the activation of tran-
scription factors in cardiac hypertrophy have
been undertaken. Because cardiac hypertrophy
is the most common response to environmen-
tal stimuli, the molecular mechanism involved
in gene regulation in cardiac hypertrophy
would have implications in myocardial
responses to environmental toxicants and pol-
lutants. The transcription factors involved in
cardiac hypertrophy include activator
protein-1 (AP-1), transcriptional enhancer
factor-1 (TEF-1), serum response factor
(SRF), nuclear factors of activated T cells
(NFATs), and GATA4 . Most of these tran-
scription factors function coordinately in
mediating extracellular signaling to regulate
hypertrophic gene expression.
AP-1 is a transcription factor composed of
Jun and Fos gene family members (73). The
AP-1 binding site is the TRE (12-O-tetra-
decanoylphorbol-13-acetate response ele-
ment), and the binding of AP-1 to the TRE
initiates transcription of the target genes (74).
In recent studies, it has been shown that ele-
vated levels of c-Jun are associated with the
stress induced by ischemia/reperfusion in car-
diomyocytes (75). In volume-overload hyper-
trophy, AP-1 plays an important role in the
regulation of Fas and FasL activities (76).
Overstretching of myocardium induces Fas
expression (77). Fas-dependent signaling
pathways are coupled to the activation of
AP-1 in isolated cardiomyocytes (76,78).
These are pathways that can lead to myocar-
dial cell apoptosis (76–79). However, there
are studies showing that activation of AP-1 is
independent of the induction of apoptosis
(80). AP-1 has been implicated in transcrip-
tional regulation of several genes associated
with a hypertrophic response (81,82). 
TEF-1 is a transcription factor that has
been shown to be activated in α1-adrenergic-
stimulated hypertrophy of cultured cardiomy-
ocytes (83). It is involved in induction of
β-myosin heavy chain (MHC) and α-skeletal
actin fetal isogenes in cardiac hypertrophy
(84). SRF has been demonstrated to be both
necessary and sufficient to mediate stretch
responses in myocardium, leading to induc-
tion of c-fos expression (85). This stretch-
induced activation of SRF was also observed
in hypotonic cell swelling, leading to c-fos
induction (86). Thus, activation of SRF may
be the general mechanism of c-fos activation
in response to increased membrane tension in
cardiac myocytes. 
NFAT3 is a member of a multigene fam-
ily that contains four members, NFATc,
NFATp, NFAT3, and NFAT4 (87). These
factors bind the consensus DNA sequence
GGAAAAT as monomers or dimers through
a Rel homology domain (88). Unlike the
other three members that are restricted in
their expression to T cells and skeletal muscle,
NFAT3 is expressed in a variety of tissues
including the heart (87,89). The role of
NFAT3 in cardiac hypertrophy has been
demonstrated recently in an elegant study
(90). Hypertrophic stimuli such as angio-
tensin II and phenylephrine cause an increase
in intracellular Ca2+ levels in myocardial cells.
This elevation in turn results in activation of
calcineurin (discussed below). NFAT3 is
localized within the cytoplasm and is dephos-
phorylated by the activated calcineurin. This
dephosphorylation enables NFAT3 to
translocate to the nucleus where it can inter-
act with GATA4. NFAT3 can also activate
some hypertrophic responsive genes through
mechanisms independent of GATA4. 
GATA factors are a family of nuclear tran-
scriptional regulatory proteins that are related
structurally within a central DNA-binding
domain but are restricted in expression to dis-
tinct sets of cell types (91). Currently, six dif-
ferent family members have been characterized
in vertebrate species. They are GATA1, 2, 3, 4,
5, and 6. Each protein contains two similar
repeats of a highly conserved zinc finger of
the form CXNCX6LWRRX7CNAC. The
c-terminal repeat constitutes a minimal DNA-
binding domain sufficient for sequence-spe-
cific recognition of a “GATA” cis-element,
usually (A/T)GATA(A/G) or a related DNA
sequence, present in promoters and/or
enhancers of target genes (92). It has been
shown that GATA1, 2, and 3 mainly regulate
various aspects of hematopoiesis (93), whereas
the GATA4, 5, and 6 factors are involved in
regulation of cardiogenesis (91). The signiﬁ-
cance of GATA4 in regulation of hyper-
trophic response in myocardial cells has been
demonstrated recently (94). Cardiac hypertro-
phy induced by angiotensin II is mediated by
an angiotensin II type1a receptor (AT1aR). A
GATA motif was identiﬁed in the AT1aR pro-
moter. Mutations introduced into the consen-
sus binding site for GATA factor abolished
the pressure overload response (94).
Moreover, it has been demonstrated that the
interactions between AP-1 and GATA4 and
between NFAT3 and GATA4 are essential in
myocardial hypertrophic responses (90,94). 
Molecular Basis for Alterations in
Myocardial Structure and Function
It has been demonstrated that reprogram-
ming of gene expression of β-MHC and
α-skeletal actin is associated with myocardial
hypertrophy (69–72,95). Upregulation of
these fetal protein isoforms is associated with
downregulation of the corresponding adult
isoforms, α-MHC and α-cardiac actin (96).
These molecular processes are correlated with
the development of hypertrophy and the
thickness of the ventricular wall, which has
been shown to result from an increase in cell
size due to an increase in the number of sar-
comeres and mitochondria within the cell
(97). This hypertrophic development leads to
tissue hypoperfusion, which in turn results in
the activation of compensatory mechanisms
such as the sympathetic nerve system and the
renin–angiotensin system.
The neurohumoral compensatory
response activates counter regulatory hor-
mones such as ANP and b-type natriuretic
peptide (BNP) (98). The long-term expres-
sion of these hormones, particularly ANP and
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BNP, is associated with numerous detrimental
biological effects that eventually lead to car-
diac failure by way of myocyte dysfunction,
apoptosis, and cell loss (99). For instance, the
ANP gene is expressed in both atrium and
ventricle during embryonic development, but
its expression is downregulated in the ventri-
cle shortly after birth, leaving the atrium as
the primary site of ANP synthesis within the
mature myocardium (100). During myocar-
dial pathologic remodeling, reexpression of
ANP in myocytes of the left ventricle takes
place (99–101). Recent studies have demon-
strated that ANP is a factor responsible for
myocardial apoptosis (49,102). Moreover,
apoptosis plays a critical role in the develop-
ment of heart failure (38–42,103,104).
Therefore, serum concentrations of ANP
have been monitored experimentally and clin-
ically and serve as important indices of heart
failure (99–101,105).
Signaling Pathways Leading
to Cardiotoxicity
Mitochondrial Factors in Myocardial
Cell Death 
Recent studies (106,107) have focused on
mitochondrial factors in myocardial cell
death. Current knowledge obtained from cut-
ting-edge experimental approaches suggests
that signaling pathways mediating oxidative
stress-induced myocardial cell death can be
divided into those that trigger the early events
of cell loss and those that result in severe, end-
stage myocardial cell death. Cytochrome c and
pro-caspase-3 are preexisting factors that are
activated by environmental toxic insults. 
Mitochondrial permeability transition
(MPT) occurs under toxic insults (108).
This MPT behaves like a membrane pore
that allows diffusion of solutes < 1,500 Da
in size. Although MPT can occur as a tem-
porary event, it can rapidly become irre-
versible, with the resulting loss of
mitochondrial homeostasis and high-ampli-
tude mitochondrial swelling. Because the
inner membrane has a larger surface area
than the outer membrane, mitochondrial
swelling can cause rupture of the outer
membrane, releasing intermembrane pro-
teins into the cytosol (109). Among the
intermembrane proteins is cytochrome c.
Another possible mechanism that leads to
mitochondrial cytochrome c release is the
action of Bax, a proapoptotic protein of the
Bcl-2 family (110). Overexpression of Bax
under oxidative stress conditions has been
observed in a number of studies using differ-
ent organs including the heart (111,112). It
has been shown that Bax is translocated
from cytosol to mitochondria and forms
pores in mitochondrial outer membranes,
leaving the inner membranes intact (113).
This mechanism implies that Bax-mediated
cytochrome c release is independent of MPT
(114). The release of cytochrome c from
mitochondria into the cytosol is a critical
initiation step in myocardial apoptosis.
Cytochrome c aggregates with apoptotic
protease-activating factor-1 (another factor
released from mitochondria under oxidative
stress), procaspase-9, and deoxyadenosine
triphosphate (dATP), and subsequently acti-
vates caspase-9, which activates caspase-3. In
our recent studies, we detected a significant
decrease in cytochrome c concentrations in
mitochondria and a concurrent increase in
the cytosol by Western blot analysis in
adriamycin-treated cardiomyocytes (115). 
To determine the significance of the
caspase–3-activated apoptotic pathway in the
pathogenesis of cardiomyopathy, we have used
a caspase–3-specific inhibitor, Ac-DEVD-
cmk, to determine its effect on adriamycin-
induced myocardial cell death. Cultured
cardiomyocytes isolated from neonatal mice
were treated with Ac-DEVD-cmk before adri-
amycin treatment. This inhibitor efficiently
suppressed caspase-3 activity and reduced the
number of apoptotic cells in cultures (115). 
Inhibition of caspase–3-activated apoptotic
pathway, however, may not abort ultimate cell
death because of necrosis that can also be trig-
gered by MPT and mitochondrial cytochrome
c release. The loss of cytochrome c blocks elec-
tron transport, leading to decreased production
of ATP and eventually ATP depletion, which
results in necrosis. Enhanced necrotic cell
death in the presence of caspase-3 inhibitor has
been observed in our recent studies examining
adriamycin cardiotoxicity. There is another
group of proapoptotic factors that are released
from mitochondria, but the mechanisms of
action of these factors are unclear. These are
apoptosis-inducing factors (AIF). It has been
shown that AIF may directly translocate to the
nucleus after they are released from mitochon-
dria, causing DNA framentation (116). These
multiple pathways mediated by mitochondrial
factors suggest that there is a bewildering diver-
sity of cell death paradigms. In particular,
under chronic environmental toxic insults, the
relative importance of mitochondrial electron
transport defects, MPT, cytochrome c leakage,
and nonmitochondrial factors needs to be care-
fully examined. An important clinical consid-
eration is whether caspase inhibitors can offer
long-term protection against cell death, as
delineated in Figure 2. It is thus important to
deﬁne the most efﬁcient therapeutic strategy in
blocking myocardial cell death rather than in
inhibiting a particular cell death program. 
Cytokines and Other Factors in
Myocardial Death Signaling 
Cytokines have been shown to be associated
with the pathogenesis of acute coronary
syndromes (117) and chronic heart failure
(118). In both cases, myocardial cell loss is
the essential feature of the disease. Increased
serum concentrations of proinflammatory
cytokines such as tumor necrosis factor-α
(TNF-α) have been found in chronic heart
failure (119). Another biomarker of chronic
heart failure is the increased serum concentra-
tions of Fas ligand (120). Both TNF-α and
Fas ligand induce apoptosis of cardiomy-
ocytes in various experimental studies
(120,121). Other cytokines such as inter-
leukin-6 are also found in the serum of
patients with failing hearts (122–124). 
TNF-α is the most studied cytokine in
myocardial cell death signaling pathways.
Cardiomyocytes are both the source and the
target of this cytokine (125). The proinﬂam-
matory cytokines interleukin-1, interleukin-2
and interferon-γ can induce TNF production
from target cells, including cardiomyocytes
(116). The most important role of TNF-α in
chronic heart failure is the induction of
myocardial cell apoptosis (125–127). The path-
way leading to TNF–α-induced myocardial
apoptosis is mediated by TNF receptors,
TNFR1 and TNFR2 (128). Activation of these
receptors leads to activation of caspase-8 (129).
A BH3 domain-containing proapoptotic Bcl2
family member, BID, is then cleaved by cas-
pase-8 (130). The truncated BID is translo-
cated from cytosol to mitochondria, inducing
ﬁrst the clustering of mitochondria around the
nuclei and release of cytochrome c, and then
the loss of mitochondrial membrane potential,
cell shrinkage, and nuclear condensation, i.e.,
apoptosis (130). Caspase-8 also directly
activates caspase-3, leading to apoptosis (131).
Figure 2. Mitochondrial factor-mediated apoptosis and
necrosis. Note that mitochondrial cytochrome c release
can lead to activation of caspase-3 as well as decreased
production of ATP. Inhibition of caspase-3 by Ac-DEVD-
cmk would thus inhibit the apoptotic pathway but
enhance the ATP-depletion-induced necrosis if the stim-
ulus for cytochrome c release persists. Cyclosporin A
can inhibit MPT formation and thereby suppress
cytochrome c release. 
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Interleukin-6 is a multifunctional pro-
inflammatory cytokine that mediates both
immune and inflammatory responses.
Elevated serum concentrations of inter-
leukin-6 have been observed in patients with
heart failure (126,132). A new member of the
interleukin-6 receptor family of cytokines,
cardiotrophin-1, has been cloned recently
(133). This is added to the list of other mem-
bers of this family, including interleukin-6,
interleukin-11, leukemia inhibitory factor,
oncostatin, and ciliary neurotrophic factor.
Cardiotrophin-1 acts as a nerve growth factor
and also induces hypertrophy of cardiac
myocytes (134,135). Interestingly, car-
diotrophin-1 has been shown to inhibit
cytokine-induced apoptosis in vitro (136).
Further studies are needed to investigate its
role in myocardial disease conditions. 
Endothelin-1 is importantly involved in
cardiomyopathy. It is produced within both
failing and nonfailing hearts from several
types of cells, including endothelial cells
(137), endocardium, and myocytes (138). It
has been considered that limited expression of
endothelin-1 within the myocardium is an
adaptive response to stress, providing
increased inotropic support for the cardiac
myocyte (139,140) as well as increasing the
rate of myocyte protein synthesis (141).
Overexpression of endothelin-1, however,
eventually becomes maladaptive by producing
focal vasospasm, myocytosis, and increased
myocardial fibrosis (142). In a rat model, it
has been shown that myocardial infarction is
accompanied with overexpression of endothe-
lin-1 and that selective inhibition of the
endothelin-A receptor with a speciﬁc antago-
nist (BQ-123) improved long-term survival
of these animals (143).
Sarcoplasmic Reticulum Pathway
Leading to Apoptosis 
This pathway was identiﬁed recently (144). It
was shown that caspase-12 is localized in the
endoplasmic reticulum (ER) and activated by
ER stress. This stress includes disruption of
ER calcium homeostasis and accumulation of
excessive proteins in the ER. Mice deficient
in caspase-12 are resistant to ER stress-
induced apoptosis. Therefore, caspase-12
mediates an ER-specific apoptotic pathway.
This pathway would have a large impact on
myocardial cells and should be investigated in
the future. 
Role of Calcium in Cardiotoxicity 
This topic has been the most discussed and
investigated in cardiotoxicologic research.
However, our understanding of the role of
calcium in cardiotoxicity is rather superﬁcial.
When carefully examining the current litera-
ture, one ﬁnds that there are few mechanistic
studies that specifically probe the role of
calcium in cardiotoxicity. Yet, numerous
studies have implicated intracellular Ca2+ as a
signal for cardiac responses to environmental
toxic insults (145–147). In response to
myocardial stress by environmental stimuli,
calcium concentrations are increased in the
myocardial cells (148). This is consistent with
the speculation that Ca2+ coordinates physio-
logic responses to stresses. Many other specu-
lations are derived from the studies
examining the role of calcium in toxicologic
responses in other systems. The unique action
of calcium in cardiotoxicity, however, has to
be studied speciﬁcally.
Recently there has been a breakthrough in
understanding the role of calcium in mediating
myocardial hypertrophic signals (90). A sus-
tained increase in intracellular Ca2+ concentra-
tions activates calcineurin. Calcineurin is a
ubiquitously expressed serine/threonine phos-
phatase that exists as a heterodimer, comprised
of a 59-kDa calcium-binding catalytic A sub-
unit and a 19-kDa Ca2+-binding regulatory B
subunit (149). Activation of calcineurin is
mediated by binding of Ca2+ and calmodulin
to the regulatory and catalytic subunits, respec-
tively. A toxicologic signiﬁcance of calcineurin
is that it is activated by a sustained Ca2+ eleva-
tion and is insensitive to transient Ca2+ ﬂuxes
such as those that occur in response to
cardiomyocyte contraction (90). 
Numerous studies have demonstrated
important roles for Ras, mitogen-activated
protein kinase (MAPK), and protein kinase
C (PKC) signaling pathways in myocardial
responses to hypertrophic stimuli (150,151).
All these signal transduction pathways are
associated with an inotropic increase in intra-
cellular Ca2+ concentrations (152). The
coordinating role of calcium in cardiac
hypertrophic response was speculated in a
recent study (90) as follows. Hypertrophic
stimuli such as angiotensin II and phenyl-
ephrine cause an elevation of intracellular
Ca2+ that results in activation of calcineurin.
A series of reactions occurs through the acti-
vated calcineurin, including dephosphoryla-
tion of NFAT3 and its translocation to
nucleus where it can interact with GATA4
(90). Calcineurin could also act through an
NFAT-independent mechanism to regulate
myocardial hypertrophy. 
Protein Kinase C and the Myocardial
Signaling Pathway 
PKC and the myocardial signaling pathway
are among the most extensively studied topics
in cardiac research. Most cardiotoxicologic
studies have adapted the concept of cardiac
physiologic studies in examining the role of
PKC in mediating toxic signals. Several excel-
lent reviews are available on PKC in myocar-
dial signaling pathways leading to cardiac
hypertrophy and heart failure (153–157).
Therefore, this topic will not be included in
this review. 
Oxidative Stress and Mitogen-Activated
Protein Kinases 
Oxidative stress and MAPKs are involved in
myocardial remodeling and play a major role
in the development of cardiotoxicity. Among
the MAPKs, p38 MAPK has been extensively
studied in myocardial apoptosis. The p38
MAPK is a subfamily of the MAPK super-
family and is stress responsive. This subfamily
consists of p38α, p38β, p38γ, and p38δ
(158,159). Recent studies have identiﬁed p38
MAPK as an important group of signaling
molecules that mediate environmental stress
responses in various cell types (160,161). In
noncardiac cells, p38 MAPK has been impli-
cated in gene expression, morphologic
changes, and cell death in response to endo-
toxin, cytokines, physical stress, and chemical
insults (162–164). In cardiac cells, it has been
reported that p38 MAPK is associated with
the onset of apoptosis in ischemia–reperfu-
sion-treated hearts (165,166). In particular,
transfection experiments using primary cul-
tures of neonatal rat cardiomyocytes have
shown that p38α is critically involved in
myocyte apoptosis (167). In any event, the
common observation is that p38 MAPK acti-
vation is associated with accumulation of
reactive oxygen species generated under stress
conditions. In this context, we have examined
the possible role of p38 MAPK in mediating
adriamycin-induced myocardial apoptosis.
Treatment with adriamycin significantly
induced apoptosis in neonatal cardiomyocyte
cultures and activated p38 MAPK (61). That
p38 MAPK was involved at least in part in
the adriamycin-induced myocyte apoptosis
was demonstrated by two important observa-
tions (61). First, a time-course analysis
revealed that p38 MAPK activation preceded
the onset of apoptosis. A sensitive and early
apoptosis detection method of Annexin
V-FITC has been used to detect the onset of
myocyte apoptosis. It was demonstrated that
as early as 30 min after adriamycin treatment,
myocyte apoptosis occurred. The early detec-
tion of p38 MAPK activation by a sensitive
FITC-conjugated anti–phospho-p38 anti-
body and confocal microscopy was observed
20 min after adriamycin treatment. Second,
application of SB203580, a speciﬁc inhibitor
of p38 MAPK, significantly inhibited
adriamycin-induced myocyte apoptosis.
Because SB203580 acts as a speciﬁc inhibitor
of p38α and p38β but not p38γ and p38δ,
the involvement of the former specific iso-
forms of p38 MAPK in the adriamycin-
induced myocyte apoptosis are implicated.
Recent studies have identified that p38α is
speciﬁcally involved in apoptosis of neonatal
rat cardiomyocytes in primary cultures and
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p38β mediates hypertrophy of these cells
(167). Further studies are required to deter-
mine which speciﬁc isoform(s) of p38 MAPK
are essential in the signaling pathway of
adriamycin-induced apoptosis.
An important novel observation in our
recent studies is that metallothionein (MT),
an important antioxidant, inhibited both
apoptosis and p38 MAPK activation by adri-
amycin in cardiomyocytes (61). Although
adriamycin-induced apoptosis was partially
inhibited (by 50%), the activation of p38
MAPK was almost completely blocked by
MT. Taken together, these observations sug-
gest that oxidative stress-activated p38 MAPK
plays a crucial role in myocardial apoptosis. 
Conclusion
Myocardial responses to detrimental environ-
mental insults lead to myocardial apoptosis or
necrosis, remodeling, and heart failure. The
current understanding of the cardiac toxic
effects is, however, superficial. Most of the
cardiotoxicologic studies have been descrip-
tive. Any agent, either physical or chemical,
can trigger myocardial responses. However,
these responses may not necessarily be toxic.
On the other hand, there is no single agent
that only triggers toxic responses. Of note,
cellular responses to toxic insults always start
with initiation of protective mechanisms. The
toxic end points are the ultimate outcome of
the balance between cytoprotection and the
insult. Therefore, it is critical to identify the
true toxic end point of cardiotoxicity. Many
intermediate responses, however, can lead to
either protective or injurious responses. For
example, p38 MAPK activation can lead to
cytoprotection against oxidative stress by acti-
vating transcription factors that upregulate
protective mechanisms or cause cell death by
activating apoptotic programs. It is well
known that multiple signaling pathways exist
and are activated in response to stresses. One
cannot define which pathway mediates the
toxic response or the protective action. In this
context, inhibition of one pathway may acti-
vate the other. For instance, inhibition of
caspase-3 can abort apoptosis if caspase-3 is a
key element in a particular apoptotic signal-
ing pathway. This inhibition may shift the
apoptotic program to necrotic if mitochondr-
ial cytochrome c release is a critical upstream
event that leads to caspase-3 activation. Thus,
an important consideration in preventing
myocardial cell death induced by environ-
mental toxicants and pollutants is not an
inhibition of a particular cell death program
but rather the ultimate survival of a cell.
Further extensive studies of the molecular
mechanisms and signaling transduction path-
ways of cardiotoxicity are warranted.
Advances in molecular biology and the avail-
able cutting-edge experimental approaches
will provide powerful tools for such studies. It
is probable that signiﬁcant insights into car-
diotoxicity will be obtained in the near
future. A comprehensive understanding of
cardiotoxicity will greatly contribute to the
advance of cardiac medicine.
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